Difference between revisions of "Health impact modelling: ultraviolet radiation and melanoma skin cancer"
Iranjon 95 (talk | contribs) (→Explanation) |
(link to IEAHIAS added) |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
{{assessment|moderator=Jouni Tuomisto}} | {{assessment|moderator=Jouni Tuomisto}} | ||
| + | :''This case study was carried out as part (work package 3.7) of the EU-funded INTARESE project. The contents were obtained from [http://www.integrated-assessment.eu/resource_centre/health_impact_modelling_ultraviolet_radiation_and_non_melanoma_skin_cancer IEHIAS toolbox]. | ||
{{summary box | {{summary box | ||
| Line 20: | Line 21: | ||
INTARESE PROJECT-WP3.7-UVR | INTARESE PROJECT-WP3.7-UVR | ||
| − | |||
| − | + | Several health impact model runs were carried out. The baseline model and model 1 used the baseline incidence rates per age group and gender. For model 2, future incidence rate per age group and gender were calculated by applying the BAF and the future percental change in modelled ambient UVR to the baseline incidence rates. The (future) incidence rates were combined with the baseline and future population estimates in order to calculate skin cancer incidence (number of cases). | |
| − | + | The results were then combined with the baseline and future population estimates in order to calculate skin cancer incidence (number of cases). Thus: | |
| − | + | * Baseline model: baseline incidence rates and baseline population estimates are applied. | |
| − | + | * Model 1: baseline incidence rates and future population estimates are applied. | |
| − | + | * Model 2: estimated future incidence rates and future population estimates are applied. | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| + | The input data sheet includes the population (in thousands) data for males and females developed in baseline; 2030 and 2050 B1, and 2030 and 2050 A2. The data also includes the baseline incidence rate per 10000 per year and the incidence mortality ratio for both males and females in all the scenarios. The calculations were carried by dividing the age range starting from 0 – 85+ into a 5-year age group for both the sexes. | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | The summery tables include the data for both health impact model 1 and 2. The data derived from the calculation of attributable incident cases, attributable deaths and attributable DALY were presented both individually and together for males and females. The attributable incident cases, mortality rate and DALY were also calculated per million combining both males and females. The data were explored for 2001 and 2030 B1 and A2, 2050 B1 and A2, except for the attributable DALY data which was for 2001 and 2030 B1 and A2. | |
| − | + | The summery figures contain data for health impact model 1 and 2, including the total incidence, mortality and DALY for males and females together. The total incidence, mortality and DALY rate per million for both males and females were also calculated. The calculations was for 2001, 2030 B1 and A2 and 2050 B1 and A2, except for the DALYs which was for 2001 and 2030 B1 and A2. Data were illustrated graphically and also presented in tables. | |
| − | |||
| − | |||
| − | |||
| − | + | The health impact model 2 incidence rate per 100000 includes data for males and females; dividing the 0-85+ age range into 5-year age groups individually for both sexes. The calculation was performed for baseline, B1 (2030, 2050) and A2 (2030, 2050). | |
| − | |||
| − | |||
| + | The attributable (based on PAF) and the total incidence cases, number of deaths and incidence and mortality rates per 100000 per year were calculated individually for baseline, model 1 B1 2030, model 1 B1 2050, model 1 A2 2030, model 1 A2 2050, model 2 B1 2030, model 2 A2 2030 and model 2 A2 2050. The age range was 0-85+ for both males and females which was categorised into 5-year age group for both attributable and total data in all the respective scenarios. | ||
==See Also== | ==See Also== | ||
| Line 514: | Line 54: | ||
| − | == | + | ==References== |
*[[Scotto, J. and T. Fears 1987 The association of solar ultraviolet and skin melanoma incidence among Caucasians In the United States. Cancer Investigation 5(4), 275-283.]] | *[[Scotto, J. and T. Fears 1987 The association of solar ultraviolet and skin melanoma incidence among Caucasians In the United States. Cancer Investigation 5(4), 275-283.]] | ||
*[[Lucas, R., T. McMichael, et al. 2006 Solar ultraviolet radiation: Global burden of disease from solar ultraviolet radiation. Geneva:, World Health Organization.]] | *[[Lucas, R., T. McMichael, et al. 2006 Solar ultraviolet radiation: Global burden of disease from solar ultraviolet radiation. Geneva:, World Health Organization.]] | ||
| + | |||
| + | <references/> | ||
| + | |||
| + | ==Related files== | ||
| + | |||
| + | {{mfiles}} | ||
| + | |||
| + | {{eracedu}} | ||
Latest revision as of 11:59, 14 February 2012
This page is a assessment.
The page identifier is Op_en5390 |
|---|
| Moderator:Jouni Tuomisto (see all) |
|
Give your opinion to the peer rating of the content of this page. |
| Upload data
|
- This case study was carried out as part (work package 3.7) of the EU-funded INTARESE project. The contents were obtained from IEHIAS toolbox.
| Main message: |
|---|
| Question:
What was the overall health impact of exposures to ultra-violet radiation (UVR) under different climate change scenarios? Given current knowledge, The assessment considered two sets of scenarios for the years 2030 and 2050: the IPCC SRES B1 scenario and SRES A2 scenario.Results suggest that further knowledge about the uncertain variables considered very likely would not have changed the decision |
Scope
As part of the EU-funded INTARESE project, which contributed to the development of this Toolbox, a case study was carried out to assess health impacts of exposures to ultra-violet radiation (UVR) under different climate change scenarios.
The assessment considered two sets of scenarios for the years 2030 and 2050: the IPCC SRES B1 scenario and SRES A2 scenario. Health outcomes considered were basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and malignant melanoma (CMM). Changes in UVR exposure were estimated, taking account of changes in stratospheric ozone associated with decreasing emission of ozone depleting substances and increasing emissions of CH4 and N2O. Allowance was also made for future demographic changes.
Below the methods used to model non-melanoma skin cancer are decribed. Details of the working procedures are given in the attached spreadsheet.
Explanation
INTARESE PROJECT-WP3.7-UVR
Several health impact model runs were carried out. The baseline model and model 1 used the baseline incidence rates per age group and gender. For model 2, future incidence rate per age group and gender were calculated by applying the BAF and the future percental change in modelled ambient UVR to the baseline incidence rates. The (future) incidence rates were combined with the baseline and future population estimates in order to calculate skin cancer incidence (number of cases).
The results were then combined with the baseline and future population estimates in order to calculate skin cancer incidence (number of cases). Thus:
- Baseline model: baseline incidence rates and baseline population estimates are applied.
- Model 1: baseline incidence rates and future population estimates are applied.
- Model 2: estimated future incidence rates and future population estimates are applied.
The input data sheet includes the population (in thousands) data for males and females developed in baseline; 2030 and 2050 B1, and 2030 and 2050 A2. The data also includes the baseline incidence rate per 10000 per year and the incidence mortality ratio for both males and females in all the scenarios. The calculations were carried by dividing the age range starting from 0 – 85+ into a 5-year age group for both the sexes.
The summery tables include the data for both health impact model 1 and 2. The data derived from the calculation of attributable incident cases, attributable deaths and attributable DALY were presented both individually and together for males and females. The attributable incident cases, mortality rate and DALY were also calculated per million combining both males and females. The data were explored for 2001 and 2030 B1 and A2, 2050 B1 and A2, except for the attributable DALY data which was for 2001 and 2030 B1 and A2.
The summery figures contain data for health impact model 1 and 2, including the total incidence, mortality and DALY for males and females together. The total incidence, mortality and DALY rate per million for both males and females were also calculated. The calculations was for 2001, 2030 B1 and A2 and 2050 B1 and A2, except for the DALYs which was for 2001 and 2030 B1 and A2. Data were illustrated graphically and also presented in tables.
The health impact model 2 incidence rate per 100000 includes data for males and females; dividing the 0-85+ age range into 5-year age groups individually for both sexes. The calculation was performed for baseline, B1 (2030, 2050) and A2 (2030, 2050).
The attributable (based on PAF) and the total incidence cases, number of deaths and incidence and mortality rates per 100000 per year were calculated individually for baseline, model 1 B1 2030, model 1 B1 2050, model 1 A2 2030, model 1 A2 2050, model 2 B1 2030, model 2 A2 2030 and model 2 A2 2050. The age range was 0-85+ for both males and females which was categorised into 5-year age group for both attributable and total data in all the respective scenarios.
See Also
- Changing ambient UVR and future skin cancer in London, Rome and Helsinki: melanoma skin cancer (CMM)
References
Related files
<mfanonymousfilelist></mfanonymousfilelist>
| Error creating thumbnail: Unable to save thumbnail to destination
|
Error creating thumbnail: Unable to save thumbnail to destination
|
